Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 09:30PM GMT
Release Date Price: R$48.67 (-0.59%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Dave Ricks, Chairman and CEO of Eli Lilly. Dave, welcome, and great speaking with you today.

David A. Ricks
Eli Lilly and Company - Chairman, CEO & President

Good to be here.

Questions & Answers

Christopher Thomas Schott;David A.
JPMorgan Chase & Co, Research Division - Senior Analyst

Yes. Last year, we had the big donanemab update, and I think we're hot off the presses on some CMS decision, which we won't spend too much time on today, given the great amount of time to digest that. But would love to just hear some opening remarks just as you think about Lilly's positioning heading into 2022. The company's obviously incredibly well positioned. It's been a big outperformer versus peers. And I would just love to hear how you're thinking about the business as we start the new year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot